• Andac Argon, Mert Basaran, Fulya Yaman, Yavuz Dizdar, Burak Sakar, Hakan Camlica, Sevil E Bavbek, Harzem Ozger, Emin Darendeliler, and Haluk Onat.
• Medical Oncology Department, Istanbul Medical Faculty, University of Istanbul, Istanbul, Turkey. argona@ttnet.net.tr
• Jpn. J. Clin. Oncol. 2004 Nov 1; 34 (11): 667-72.

BackgroundOlder age and axial location of Ewing's sarcoma have been reported as unfavorable prognostic factors.MethodsThe records of patients older than 15 years with the Ewing's family of tumors were reviewed retrospectively. After the induction chemotherapy consisting of alternating vincristine, adriablastin, cyclophosphamide (VAC) and etoposide, ifosfamide with mesna protection (IE), a local treatment modality was chosen based on tumor and patient characteristics.ResultsTwenty-five patients with a median age of 19 years were evaluated. Median follow-up was 26 months (range 4-58). Seventeen patients (68%) had died. In univariate analysis, factors predictive of shorter survival were the patients presenting with metastatic disease, with the primary tumor located at the pelvis, those who never achieved complete response to chemotherapy and those who had chemotherapy for <12 months. Only a negative link with pelvic location was observed in multivariate analysis [risk ratio 7.5; 95% confidence interval (CI) 1.52-37.06; P = 0.0134]. Median progression-free survival (PFS) and overall survival (OS) were 10 months (95% CI 6.2-13.8) and 14 months (95% CI 9.3-18.7), respectively. Cumulative 2-year PFS and OS were 19.0% (95% CI, SD +/-8.4) and 32.7% (95% CI, SD +/-9.8), respectively.ConclusionsThe prognosis of patients with axial Ewing's sarcoma is dismal despite an intensive, multimodality approach including multiagent, alternating chemotherapy, surgery and/or radiotherapy. A more aggressive approach should be considered for this group of Ewing's sarcoma patients.

28 keywords...

hide…